All Stories

  1. Lessons learned from conducting a multi-center lower urinary tract physiology study: the LURN experience
  2. The National Institute of Diabetes and Digestive and Kidney Diseases Celebrates Its 75th Anniversary
  3. Validation of an Automated CT Image Analysis in the Prevention of Urinary Stones with Hydration Trial
  4. Factors associated with erectile dysfunction in men with lower urinary tract symptoms (LUTS): a Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) study
  5. Unplanned Health Care Utilization after Ureteroscopy with Ureteral Stenting: Results from the Study to Enhance Understanding of Stent-Associated Symptoms Cohort
  6. Pain After Ureteroscopy Varies by Sex and Stone Location: Findings from STENTS Study
  7. Development of Prediction Models for Severe Pain and Urinary Symptoms After Ureteroscopy With Ureteral Stent Placement: Results From the STENTS Study and Initial Validation of Pain Interference
  8. Expanded Physiological Testing of the Lower Urinary Tract in Asymptomatic Women and Those With Urgency Urinary Incontinence: Findings From the LURN‐Organ Study
  9. Widespread pain phenotypes impact treatment efficacy results in randomized clinical trials for interstitial cystitis/bladder pain syndrome: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain network study
  10. Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN): An introduction to the Urinary Urgency Phenotyping Protocol LURN II
  11. Using structured problem solving to promote fluid consumption in the prevention of urinary stones with hydration (PUSH) trial
  12. Contribution of Hypersensitivity to Postureteroscopy Ureteral Stent Pain: Findings From Study to Enhance Understanding of Stent-associated Symptoms
  13. Epidemiology of Infantile Ureteropelvic Junction Obstruction in the US
  14. Naturalistic Bladder Filling Reveals Subtypes in Overactive Bladder Syndrome That Differentially Engages Urinary Urgency-Related Brain Circuits: Results From the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  15. Reply By Authors
  16. Patients’ Experiences With the Removal of a Ureteral Stent: Insights From In-depth Interviews With Participants in the USDRN STENTS Qualitative Cohort Study
  17. Relationships Between Urinary and Nonurinary Symptoms in Treatment-Seeking Women in LURN
  18. Development and validation of models predicting treatment patterns in women with urinary urgency and/or urgency incontinence: A Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study
  19. The Patient Voice: Stent Experiences After Ureteroscopy—Insights from In-Depth Interviews with Participants in the USDRN STENTS Nested Qualitative Cohort Study
  20. Risk Factors for Increased Stent-associated Symptoms Following Ureteroscopy for Urinary Stones: Results From STENTS
  21. Widespread Pain Phenotypes Impact Treatment Efficacy Results in Randomized Clinical Trials for Interstitial Cystitis/ Bladder Pain Syndrome: A MAPP Network Study
  22. Phenotyping of Urinary Urgency Patients Without Urgency Incontinence, and Their Comparison to Urgency Incontinence Patients: Findings From the LURN Study
  23. Total fluid intake, caffeine, and other bladder irritant avoidance among adults having urinary urgency with and without urgency incontinence: The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  24. Treatment patterns in women with urinary urgency and/or urgency urinary incontinence in the symptoms of Lower Urinary Tract Dysfunction Research Network Observational Cohort Study
  25. Comparing clinical bladder diaries and recalled patient reports for measuring lower urinary tract symptoms in the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  26. Evolution of healthcare costs for lower urinary tract symptoms associated with benign prostatic hyperplasia
  27. Impact of Sleep Disturbance, Physical Function, Depression and Anxiety on Male Lower Urinary Tract Symptoms: Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)
  28. Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTS
  29. Experimental Pain and Auditory Sensitivity in Overactive Bladder Syndrome: A Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Study
  30. Reply by Authors
  31. Resolution of Hydronephrosis and Pain to Predict Stone Passage for Patients With Acute Renal Colic
  32. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia
  33. Impact of COVID-19 on Prevention of Urinary Stones with Hydration (PUSH) Study: Challenges and Opportunities for Future Trials
  34. Analgesic and Opioid Use for Patients Discharged from the Emergency Department with Ureteral Stones
  35. Prevalence of Urinary Incontinence among a Nationally Representative Sample of Women, 2005–2016: Findings from the Urologic Diseases in America Project
  36. Prevention of Urinary Stones With Hydration (PUSH): Design and Rationale of a Clinical Trial
  37. Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design
  38. National Trends in Neuromodulation for Urinary Incontinence Among Insured Adult Women and Men, 2004-2013: The Urologic Diseases in America Project
  39. Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms
  40. Patient demographic and psychosocial characteristics associated with 30‐day recall of self‐reported lower urinary tract symptoms
  41. Prevalence, subtypes, and correlates of nocturia in the symptoms of Lower Urinary Tract Dysfunction Research Network cohort
  42. Accuracy of Patient Reported Stone Passage for Patients With Acute Renal Colic Treated in the Emergency Department
  43. National Trends in the Surgical Management of Urinary Incontinence among Insured Women, 2004 to 2013: The Urologic Diseases in America Project
  44. A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10
  45. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project
  46. Symptom Based Clustering of Men in the LURN Observational Cohort Study
  47. Longitudinal changes in symptom‐based female and male LUTS clusters
  48. Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses
  49. Can 7 or 30-Day Recall Questions Capture Self-Reported Lower Urinary Tract Symptoms Accurately?
  50. U.S. Adolescent and Adult Women’s Experiences Accessing and Using Toilets in Schools, Workplaces, and Public Spaces: A Multi-Site Focus Group Study to Inform Future Research in Bladder Health
  51. Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms
  52. Acyloxyacyl hydrolase modulates depressive-like behaviors through aryl hydrocarbon receptor
  53. The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations
  54. Are three‐day voiding diaries feasible and reliable? Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) cohort
  55. A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study
  56. Pediatric Urinary Stone Disease in the United States: The Urologic Diseases in America Project
  57. Strengthening Research in Benign Urology: Dispelling Myths that Impede Success
  58. A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index‐29 (LURN SI‐29) questionnaire
  59. The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms
  60. Optimization of DNA extraction from human urinary samples for mycobiome community profiling
  61. A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network
  62. Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms
  63. Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study
  64. Symptom Based Clustering of Women in the LURN Observational Cohort Study
  65. The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations
  66. Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence
  67. Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones
  68. Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study
  69. Research Needs to Understand Self-Management of Lower Urinary Tract Symptoms: Summary of NIDDK Workshop
  70. NIH research opportunities for the prevention and treatment for chronic conditions
  71. Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence
  72. MP27-09 RELATIONSHIPS BETWEEN METABOLIC FACTORS, URINARY INCONTINENCE AND OVERACTIVE BLADDER SYMPTOMS AMONG MEN AND WOMEN IN THE LURN OBSERVATIONAL COHORT STUDY
  73. Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study
  74. Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study
  75. Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review
  76. Re: Top cited articles in urology from Turkey
  77. PNFLBA-04 RANDOMIZED CLINICAL TRIAL OF TREATMENT WITH TAMSULOSIN BEGUN IN THE EMERGENCY DEPARTMENT TO PROMOTE PASSAGE OF URINARY STONES
  78. Design and challenges of a randomized clinical trial of medical expulsive therapy (tamsulosin) for urolithiasis in the emergency department
  79. Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of Urological Chronic Pelvic Pain Syndrome
  80. Advancing a Comprehensive Approach to the Study of Lower Urinary Tract Symptoms
  81. Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia
  82. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement
  83. Symptoms of Lower Urinary Tract Dysfunction Research Network
  84. Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health
  85. Do we need new patient reported measures to evaluate lower urinary tract dysfunction?
  86. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
  87. Quality of Acute Care for Patients With Urinary Stones in the United States
  88. Urinary Stone Disease: Progress, Status, and Needs
  89. Relationship between Chronic Nonurological Associated Somatic Syndromes and Symptom Severity in Urological Chronic Pelvic Pain Syndromes: Baseline Evaluation of the MAPP Study
  90. PD39-01 SEXUAL FUNCTION ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: MTOPS COHORT OF CROSS-SECTIONAL AND LONGITUDINAL DATA
  91. Emergency Department Revisits for Patients with Kidney Stones in California
  92. Re: Cross-Sectional and Longitudinal Associations of Sexual Function with Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
  93. The International Prostate Forum introduction and history
  94. Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors
  95. Cross-Sectional and Longitudinal Associations of Sexual Function with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
  96. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes
  97. The MAPP research network: design, patient characterization and operations
  98. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer
  99. Comparative Effectiveness of Shock Wave Lithotripsy and Ureteroscopy for Treating Patients With Kidney Stones
  100. Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined Therapy
  101. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer
  102. Genito-Urological Cancers in Elderly Patients
  103. Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur ...
  104. Can We Change Patient Behaviors to Improve Urological Health?
  105. Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic Hyperplasia
  106. Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States
  107. Somatostatin receptor expression in prostate carcinoma: the urological pathologist’s role in the era of personalised medicine
  108. Active surveillance for small renal tumors: Have clinical concerns been addressed so far?
  109. Positive Surgical Margins After Nephron-Sparing Surgery
  110. Lymphocytic vasculitis of the prostate transition zone
  111. Unclassified renal cell carcinoma: a report of 56 cases
  112. Basic Research in Kidney Cancer
  113. Renal Cell Carcinoma: A Changing Paradigm With a Need for Consensus
  114. ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
  115. International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma
  116. Contemporary Management of Small Renal Masses
  117. Re: Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients With Intermediate- and Hig...
  118. 70 INVITED New Approaches in Surgical Management of Renal Cancer
  119. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
  120. Management of advanced prostate cancer – new drugs
  121. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility
  122. 716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB
  123. Toxicities of Targeted Therapy and Their Management in Kidney Cancer
  124. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 tria...
  125. Reply to Kiril Trpkov, Asli Yilmaz’ Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patien...
  126. Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Tria...
  127. Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited
  128. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use
  129. Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma
  130. Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
  131. Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors
  132. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient’s Pathology and Clinical Reports
  133. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-ri...
  134. Editorial Comment on: Predicting Occult Multifocality of Renal Cell Carcinoma
  135. Re: Matthias May, Sabine Brookman-Amissah, Jan Roigas, et al. Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications. Eur Uro...
  136. Reply to Tomasso Cai, Lorenzo Giuseppe Luciani and Gianni Malossini’s Letter to the Editor re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comp...
  137. Ablative therapies in the treatment of small renal tumors: How far from standard of care?
  138. Reply from Authors re: Marko Babjuk. New Insights in Intravesical Treatment for Intermediate- and High-Risk Non–Muscle-Invasive Urothelial Bladder Carcinoma. Eur Urol 2010;57:774–6
  139. The Changing Face of Renal-Cell Carcinoma
  140. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Ri...
  141. 189 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993
  142. 1474 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993
  143. Reply to José I. Lopéz's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and ...
  144. A Critical Analysis of the Actual Role of Minimally Invasive Surgery and Active Surveillance for Kidney Cancer
  145. The Motion: Cryotherapy is an Efficient Alternative for Kidney Cancer
  146. Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better
  147. What is new in kidney cancer?
  148. Kidney cancer in the elderly
  149. Genetic profiles in renal tumors
  150. Prostate Cancer: New Insights into Minimal and Localised Disease: Active Surveillance
  151. Secondary neoplasms of the urinary system and male genital organs
  152. Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer
  153. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?
  154. Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?
  155. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance
  156. Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
  157. Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique
  158. 2009 update on the classification of renal epithelial tumors in adults
  159. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
  160. Urologic oncology in southern Europe: Perceived problems and current plans
  161. 914 PREDICTION OF PROSTATIC INVOLVEMENT BY UROTHELIAL CARCINOMA AND OF INCIDENTAL PROSTATE CANCER IN RADICAL CYSTOPROSTATECTOMIES FOR BLADDER CANCER
  162. Editorial Comment on: Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma
  163. Multigene Methylation Analysis of Conventional Renal Cell Carcinoma
  164. Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications
  165. Editorial Comment on: Results of Endoluminal Occlusion of the Inferior Vena Cava During Radical Nephrectomy and Thrombectomy
  166. Rare and unusual histological variants of prostatic carcinoma: clinical significance
  167. Will We Be Able to “Cure” Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?
  168. Editorial Comment on: Preservation of Renal Function Following Partial or Radical Nephrectomy Using 24-Hour Creatinine Clearance
  169. Splitting and Lumping Adult Renal Epithelial Tumors Can Help the Urologists in the Prognostic Risk Stratification and in the Treatment Decision-Making
  170. PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911
  171. PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911
  172. Open Partial Nephrectomy in the Management of Small Renal Masses
  173. Chairmen's Summary
  174. Renal Cell Carcinoma: Overview
  175. A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
  176. Reply to Apostolos P. Labanaris et al's Letter to the Editor re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62
  177. There has to be a Way
  178. Re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62
  179. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion
  180. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  181. Rebuttal from Authors re: Carlo Terrone, Alessandro Volpe. The Role of Pathology for Clinical Decision-Making in Renal Cell Carcinoma is Increasing. Eur Urol 2007;51:1166–8
  182. What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?
  183. Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
  184. Re: Nephroureterectomy for Treating Upper Urinary Tract Transitional Cell Carcinoma. Time to Change the Treatment Paradigm?
  185. 1728: A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
  186. The motion: Open partial nephrectomy is the standard of care for small resectable solid renal masses
  187. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  188. Editorial: Superficial Bladder Cancer
  189. Reply to Dr Özdemir’s Letter to the Editor re: Burcin Tuna, Kutsal Yorukoglu, Mehtat Unlu, M. Ugur Mungan and Ziya Kirkali, Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. Eur Urol. 2006;50:530–34
  190. Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas
  191. Puigvert: A Man with a Vision—Nephron-Sparing Surgery 30 Years Ago in Europe
  192. Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma
  193. Phase III intermittent MAB vs continuous MAB
  194. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate
  195. 2004 WHO Classification of the Renal Tumors of the Adults
  196. Expression of Cathepsin D in Bladder Carcinoma: Correlation with Pathological Features and Serum Cystatin C Levels
  197. Are We Really Making an Advance in the Treatment of Metastatic Renal Cell Carcinoma?
  198. Beyond Skeletal-Related Events
  199. Superficial Urothelial Cancer in the Prostatic Urethra
  200. Superficial Urothelial Cancer in the Prostatic Urethra
  201. Editorial: Superficial Bladder Cancer
  202. The Future of Oncological Urology in Europe: Are we Prepared?
  203. Bladder cancer: Epidemiology, staging and grading, and diagnosis
  204. Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder
  205. Echo Contrast-Enhanced Power Doppler Ultrasonography for Assessment of Angiogenesis in Renal Cell Carcinoma
  206. Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?
  207. 1,25 Dihydroxyvitamin D Receptor Expression in Superficial Transitional Cell Carcinoma of the Bladder: A Possible Prognostic Factor?
  208. Significance of COX-2 expression in human renal cell carcinoma
  209. Urothelial carcinoma of the bladder with trophoblastic differentiation: A case report
  210. Significance of heat shock protein-27 expression in patients with renal cell carcinoma
  211. Handling and Pathology Reporting of Adrenal Gland Specimens
  212. Conservative Management of Mucosal Prostatic Urethral Involvement in Patients with Superficial Transitional Cell Carcinoma of the Bladder
  213. Handling and Pathology Reporting of Renal Tumor Specimens
  214. Developments in Organ Preserving Treatments for Renal Cell Cancer: Open Surgery
  215. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder
  216. Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma
  217. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder
  218. Clinical Aspects of Renal Cell Carcinoma
  219. Renal cell carcinoma: new prognostic factors?
  220. Bone Mineral Density and Biochemical Markers of Bone in Patients With Idiopathic Hypercalciuria
  221. RE: Etiology of Spontaneous Perirenal Hemorrhage: A Meta-Analysis
  222. Transitional cell carcinoma of the ureter and renal pelvis
  223. Primary renal lymphoma of mucosa-associated lymphoid tissue
  224. Expression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer
  225. Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer
  226. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  227. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  228. Prognostic significance of nuclear morphometry in renal cell carcinoma
  229. Prognostic Significance of Estrogen Receptor Expression in Superficial Transitional Cell Carcinoma of the Urinary Bladder
  230. Management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder
  231. Phase III study of intermittent MAB versus continuous MAB international cooperative study
  232. A Prospective Survey of Surgical Approaches in Clinically Localized Renal Cell Carcinoma--A Preliminary Attempt at Surgical Quality Control
  233. Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor
  234. Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma
  235. Recent advances in kidney cancer and metastatic disease
  236. Vertebral Fracture Associated with Shockwave Lithotripsy in a Patient with Granulomatous Spondylitis
  237. INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-...
  238. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?
  239. METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA: SUBCELLULAR LOCALIZATION AND PROGNOSTIC SIGNIFICANCE
  240. Quality control of radical prostatectomy
  241. Premalignant Lesions in the Kidney
  242. Expression of PS2 Protein and Its Relation with the Ki–67 Proliferative Indices and Tumor Recurrence in Superficial Bladder Carcinomas
  243. Renal Cancer
  244. Significance of Tissue Laminin P<sub>1</sub> Elastase and Fibronectin Levels in Transitional Cell Carcinoma of the Bladder
  245. Renal Cancer
  246. Precancerous Lesions in the Kidney
  247. Ganglion cells in the human prostate
  248. Prognostic Significance of Microvascular Invasion in Localized Renal Cell Carcinoma
  249. RE: RECURRENT BILATERAL AMIODARONE INDUCED EPIDIDYMITIS
  250. Prognostic significance of angiogenesis and immunoreactivity of cathepsin d and type IV collagen in high-grade stage T1 primary bladder cancer
  251. PHARMACOLOGICAL ANALYSIS OF 5-HYDROXYTRYPTAMINE EFFECTS ON HUMAN ISOLATED URETER
  252. Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma
  253. RE
  254. RE: URINARY TRACT CANCER AND HEREDITARY NONPOLYPOSIS COLORECTAL CANCER
  255. Comparison of Microvascularization in Diagnostic Needle Biopsies and Radical Prostatectomies in Prostate Carcinoma
  256. Radical Nephrectomy with and without Lymph Node Dissection: Preliminary Results of the EORTC Randomized Phase III Protocol 30881
  257. Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume
  258. Renal Effects of Carbon Dioxide Insufflation in Rabbit Pneumoretroperitoneum Model
  259. Volume-weighted mean nuclear volume in renal cell carcinoma
  260. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  261. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  262. Renal Cell Carcinoma with Gallbladder Metastasis
  263. Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters
  264. Is Magnetic Resonance Imaging Necessary in the Staging of Prostate Cancer?
  265. Locally Recurrent Paratesticular Rhabdomyosarcoma Treated with Surgery and Radiotherapy
  266. Testicular Microlithiasis Associated with Teratocarcinoma and Intratubular Germ Cell Neoplasia: A Case Report
  267. Contractility Changes of the Deep Dorsal Penile Vein Due to Serotonin
  268. Ignificance of serum lam1nin P1 values in patients with transitional cell carcinoma of the bladder
  269. Effect of Extracorporeal Shockwave Lithotripsy on Plasma and Urine Endothelin Concentrations
  270. Bellini duct (collecting duct) carcinoma of the kidney
  271. Primary Kaposi's sarcoma of the glans penis
  272. Effectiveness of Extracorporeal Shockwave Lithotripsy in the Management of Stone-Bearing Horseshoe Kidneys
  273. 99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between99mTc-MIBI uptake and P-alvcoprotein expression in tumour tissue
  274. Cisplatin and Etoposide Chemotherapy in the Treatment of Adult Wilms’ Tumor
  275. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  276. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  277. Prostatic carcinoma presenting with painless parotid mass
  278. Influence of Serotonin on the Human Ureter: An in vitro Pharmacological Study
  279. Effect of Ejaculation on Prostate-Specific Antigen Levels in Normal Men
  280. Ferritin: A Tumor Marker Expressed by Renal Cell Carcinoma
  281. The effect of extracorporeal shock wave lithotripsy on pancreatic enzymes
  282. Magnetic resonance imaging in the staging of renal cell carcinoma
  283. Does Respiratory Gating Improve Extracorporeal Shockwave Lithotripsy Results?
  284. Beh�et's disease: Urogynecological manifestations in women
  285. Open stone surgery: Is it still a preferable procedure in the management of staghorn calculi?
  286. The effect of extracorporeal electromagnetic shock waves on renal proximal tubular function
  287. Primary signet-ring cell carcinoma of the bladder
  288. Are Obstructing Ureteral Stones More Difficult to Treat with Extracorporeal Electromagnetic Shock Wave Lithotripsy?*
  289. Extracorporeal Electromagnetic Shock Wave Lithotripsy of Ureteric Stones in Situ
  290. Carcinoma of the prostate and HLA antigens
  291. Carcinoma of the bladder in patients less than 40 years old
  292. Urological Aspects of Behcet's Disease
  293. Cysts of the Prostate, Seminal Vesicles and Diverticulum of the Ejaculatory Ducts
  294. Silent Testicular Metastasis from Carcinoma of the Prostate
  295. Tunica Vaginalis: an Aid in Hypospadias Surgery
  296. Androgen receptors in transitional cell carcinoma
  297. HLA Antigens and Transitional Cell Carcinoma of the Bladder
  298. Androgen Receptors - A Method to Measure Functional Behaviour in Human Prostatic Cancer
  299. Epidemiological Case-Control Study on the Etiology of Bladder Cancer in Turkey
  300. Urothelial Tumours of the Upper Urinary Tract
  301. Bladder agenesis
  302. Ureterorenoscopy: A new approach in the diagnosis and treatment of upper urinary tract disorders
  303. Amiodarone-Induced Sterile Epididymitis
  304. Blood Groups and Transitional Cell Carcinoma of the Upper Urinary Tract
  305. Spontaneous Kidney Rupture in Polyarteritis nodosa Report of Four Cases
  306. The use of oxybutynin in urological practice
  307. Ureteric perforation after ureteroscopy
  308. Androgen receptors in TCC
  309. Unusual Metastases of Renal Cell Carcinoma
  310. The role of delay in stage III testicular tumours
  311. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate
  312. The Role of Delay in Stage-Ill Testicular Tumors
  313. Haemoglobin F Levels in Patients with Testicular Tumours
  314. Experience with Treatment of Nonseminomatous Germ Cell Tumors of Testis in Turkey
  315. Advanced Tumors: Tumor Thrombus